Gujarat Terce Laboratories Q1 Results: Net profit rises 12% YoY to ₹205 crore

2 min read     Updated on 30 Jul 2026, 05:23 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Gujarat Terce Laboratories posted a Q1FY26 consolidated net profit of ₹205.41 crore, up 12.3% YoY, driven by a 27.6% rise in revenue to ₹4,170.47 crore. The company also scheduled its 41st AGM for August 21, 2026, with e-voting facilities available from August 18 to 20.

powered bylight_fuzz_icon
46957995

*this image is generated using AI for illustrative purposes only.

Gujarat Terce Laboratories reported a consolidated net profit of ₹205.41 crore for the quarter ended June 30, 2026, marking a 12.3% year-on-year increase from ₹183.00 crore in Q1FY25. Revenue from operations expanded to ₹4,170.47 crore, up from ₹3,267.96 crore in the corresponding period last year. The growth reflects strong operational performance across its chemical manufacturing segments, with earnings per share (EPS) standing at ₹0.42.

The results were approved by the Board of Directors and reviewed by the Audit Committee. The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The statutory auditors carried out a limited review of the unaudited financial results. The full format of the financial results has been filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Highlights

Particulars Q1FY26 Q4FY26 Q1FY25 FY25
Revenue from operations (₹ cr) 4,170.47 3,874.65 3,267.96 14,264.20
Net Profit After Tax (₹ cr) 205.41 119.74 183.00 678.03
EPS Basic & Diluted (₹) 0.42 0.25 0.45 1.39

Standalone revenue from operations remained consistent with consolidated figures at ₹4,170.47 crore. Standalone profit after tax was reported at ₹205.73 crore, compared to ₹183.21 crore in Q1FY25. The paid-up equity share capital stands at ₹4,881.00 crore, with a face value of ₹10 per share.

Corporate Actions

The company announced that its 41st Annual General Meeting (AGM) will be held on Friday, August 21, 2026, at 12:00 noon via Video Conferencing/Other Audio Visual Means (VC/OAVM). Members are provided with the facility to cast their votes using the electronic voting system provided by Bigshare Services Private Limited. The remote e-voting period commences on Tuesday, August 18, 2026, at 9:00 a.m. and ends on Thursday, August 20, 2026, at 5:00 p.m.

The Register of Members and Share Transfer Books will remain closed from Saturday, August 15, 2026, to Friday, August 21, 2026, both days inclusive, for the purpose of the AGM. The cut-off date for determining voting rights is Friday, August 14, 2026. Shareholders holding shares as on this date are eligible to vote. The notice convening the AGM and the annual report are available on the company’s website at www.gujaratterce.in .

What the Numbers Show

The 27.6% year-on-year growth in revenue from operations outpaced the 12.3% growth in net profit after tax, suggesting a slight compression in net margins during the quarter. While top-line expansion was robust, the lower proportional increase in bottom-line earnings indicates potential pressure on operating efficiencies or higher input costs relative to sales growth. Investors should monitor subsequent quarters to determine if this margin trend persists or if operational leverage improves as revenue scales further.

Historical Stock Returns for Gujarat Terce Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.30%+3.57%+1.12%-18.52%-28.29%+189.07%

What specific factors contributed to the compression in net margins despite the 27.6% revenue growth, and are these driven by rising raw material costs or pricing pressures?

How does Gujarat Terce Laboratories plan to leverage its increased revenue scale to improve operational efficiency and restore net profit margins in subsequent quarters?

Given the strong Q1FY26 performance, what is the management's guidance for full-year FY26 revenue and profitability targets?

Gujarat Terce Laboratories
View Company Insights
View All News
like16
dislike

Gujarat Terce Labs returns to profitability in FY26 with net profit of ₹220.17 lakh

2 min read     Updated on 03 Jun 2026, 04:51 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Gujarat Terce Laboratories Limited returned to profitability in FY26 with a net profit of ₹220.17 lakh, compared to a loss of ₹97.87 lakh in the previous year. Revenue from operations decreased to ₹4747.27 lakh from ₹5019.52 lakh in FY25. The company's EBITDA improved to ₹363 lakh, and net worth grew by over 50%, supported by improved earnings and a stronger capital structure.

powered bylight_fuzz_icon
41348258

*this image is generated using AI for illustrative purposes only.

Gujarat Terce Laboratories Limited has returned to profitability in the financial year ended 31 March 2026, reporting a net profit of ₹220.17 lakh compared to a loss of ₹97.87 lakh in the previous year. The company's board approved the annual audited standalone financial results at a meeting held on 29 May 2026. Revenue from operations for the year stood at ₹4747.27 lakh, a decrease from ₹5019.52 lakh in FY25, while total revenue was ₹4781.31 lakh.

The statutory auditor, Shah Doshi Patel & Associates LLP, issued an unmodified opinion on the financial results. The company reported an exceptional item of ₹45.39 lakh during the year, attributed to a one-time increase in provision for employee benefits due to the New Labour Codes. For the fourth quarter ended 31 March 2026, the company posted a profit after tax of ₹10.10 lakh, with revenue from operations at ₹1139.93 lakh.

Period Revenue from Operations (₹ in Lakhs) Total Revenue (₹ in Lakhs) Net Profit/(Loss) (₹ in Lakhs)
FY26 (Audited) 4747.27 4781.31 220.17
FY25 (Audited) 5019.52 5050.30 (97.87)
Q4 FY26 (Audited) 1139.93 1147.59 10.10
Q4 FY25 (Audited) 1232.44 1241.11 (339.14)

The board meeting, which commenced at 3:00 p.m. and concluded at 8:31 p.m. on 29 May 2026, was conducted in compliance with Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Company Secretary Ashka Solanki. The company's earnings per share (EPS) for the year improved to ₹2.92 basic and diluted from a negative ₹1.32 and ₹1.26 respectively in the prior year.

Management Commentary

In an investor presentation released on 3 June 2026, the company highlighted that FY26 was a year of strengthening fundamentals and improving earnings quality. While revenue declined by 5% over FY25, the strategic focus on profitability and operational efficiency resulted in an EBITDA of ₹363 lakh. The company's net worth strengthened by over 50% during the year, supported by improved earnings and a stronger capital structure. Prudent financial discipline led to lower finance costs, improved liquidity, and positive operating cash generation.

The fourth quarter was relatively challenging, with revenue of ₹1,140 lakh and EBITDA of ₹37 lakh. However, the quarter concluded with a positive PAT, reflecting the resilience of the business and the benefits of structural improvements implemented over the past year. The company continues to focus on strengthening brand equity, improving field productivity, and maintaining financial discipline to create a stronger platform for sustainable value creation.

Historical Stock Returns for Gujarat Terce Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.30%+3.57%+1.12%-18.52%-28.29%+189.07%

What specific operational efficiency measures drove the turnaround to profitability despite the 5% decline in revenue?

How will the company address the revenue decline to ensure top-line growth aligns with its improved profitability in FY27?

What is the strategic outlook for managing the one-time increase in employee benefit provisions under the New Labour Codes moving forward?

Gujarat Terce Laboratories
View Company Insights
View All News
like17
dislike

More News on Gujarat Terce Laboratories

1 Year Returns:-28.29%